EISAI to Unveil New Data on Halaven® (Eribulin) Mode of Action at San Antonio Breast Cancer Symposium 2015 (SABCS) (1)

HATFIELD, England, December 2, 2015 /PRNewswire/ --

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/AUSTRIAN/U.S. JOURNALISTS 

Studies at the upcoming San Antonio Breast Cancer Symposium (Texas, 8-11 December)

will explore mode of action and highlight potential new combinations  

New data at the San Antonio Breast Cancer Symposium (SABCS) will explore the distinct mode of action of Halaven(R) (eribulin) in which the epithelial-to-mesenchymal transition is reversed, the process by which cancerous cells are made more aggressive and harder to treat. The full results of the study, called "Eribulin affects E-cadherin localization consistent with a reversal of the epithelial-to-mesenchymal transition" will be presented as a poster (P5-03-09) at the conference on Friday 11 December (17:00-19:00 CST).

Eisai will present a total of seventeen eribulin abstracts at SABCS. Eribulin is currently indicated in Europe for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.[1]

A further study of stage I-II Hormone receptor positive/Her2 negative breast cancer to be presented at SABCS has data suggesting that women with the aggressive, Luminal B form of the disease might benefit the most from treatment on eribulin which induces a luminal A phenotype. The study, "Efficacy and gene expression results from eribulin  SOLTI1007 neoadjuvant study [https://clinicaltrials.gov/ct2/show/NCT0... ] ", will be presented as a poster (P3-07-66) at the conference on Thursday 10 December (17:00 - 19:00 CST).

A number of other studies to be presented at SABCS will also highlight the potential of eribulin to work in combination with other therapies. One study will present the design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. A second study will explore whether PH20 (PEGPH20) (Pegylated Recombinant Human Hyaluronidase) enhances efficacy of eribulin in triple negative breast cancer xenografts.

The full details of the seventeen eribulin abstracts are as follows:

(CONTINUA)